Chronic migraineurs form carboxyhemefibrinogen and iron-bound fibrinogen

Vance G Nielsen, Wendi Kulin, John Samuel Lawall, Felesia Nancy Macfarland, Andrew Chen, Heidi Adelleen Hadley, Adam James Dadeppo, Evangelina Barbara Steinbrenner, Ryan William Matika

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Chronic migraine (CM) is a disabling painful condition that is associated with dementia and thrombotic disease. It has been proposed that carbon monoxide (CO) and iron may play a role in CM, and CO and iron are products of the heme oxygenase system which is widespread within the brain. Further, CO and iron enhance plasmatic coagulation in part via a fibrinogen-dependent mechanism. Thus, our goal was to determine whether patients with CM had experienced carboxyhemefibrinogen formation, iron bound fibrinogen formation and plasmatic hypercoagulability. Nonsmokers with CM were recruited after informed, written consent. Blood was collected, anticoagulated with sodium citrate, and then centrifuged with plasma stored at -80ºC. Carboxyhemefibrinogen formation, iron bound fibrinogen formation and coagulation kinetics were determined via thrombelastographic methods. Patient results were compared with laboratory values generated from normal control plasmas. Incidence (95% confidence intervals) of the various parameters was determined using the Clopper-Pearson method. Twenty-six CM patients (24 female) were recruited; they were 46±12 years old. With regard to fibrinogen modification, 88.5% (69.8%-97.6%) of CM patients had formation of carboxyhemefibrinogen, iron bound fibrinogen, or both. With regard to coagulation, 42.3% (23.4%-63.1%) of patients had abnormally decreased time to clot initiation, 80.8% (60.6%-93.4%) had abnormally large velocity of clot formation, and 46.2% (26.6%-66.7%) had abnormally strong clot strength. Patients with CM have a large incidence of carboxyhemefibrinogen and iron bound fibrinogen formation and hypercoagulability. Confirmatory and potential therapeutic clinical trials targeting CO and iron modified hypercoagulation as a source of pain and vascular disease in CM patients are indicated.

Original languageEnglish (US)
Pages (from-to)1079-1085
Number of pages7
JournalCNS and Neurological Disorders - Drug Targets
Volume14
Issue number8
StatePublished - Oct 1 2015

Fingerprint

Migraine Disorders
Fibrinogen
Iron
Carbon Monoxide
Thrombophilia
Heme Oxygenase (Decyclizing)
Incidence
Informed Consent
Vascular Diseases
Dementia
Reference Values
Clinical Trials
Confidence Intervals
Pain
Brain

Keywords

  • Carbon monoxide
  • Fibrinogen
  • Iron
  • Migraine
  • Thrombelastography
  • Vascular disease

ASJC Scopus subject areas

  • Neuroscience(all)
  • Pharmacology

Cite this

Nielsen, V. G., Kulin, W., Lawall, J. S., Macfarland, F. N., Chen, A., Hadley, H. A., ... Matika, R. W. (2015). Chronic migraineurs form carboxyhemefibrinogen and iron-bound fibrinogen. CNS and Neurological Disorders - Drug Targets, 14(8), 1079-1085.

Chronic migraineurs form carboxyhemefibrinogen and iron-bound fibrinogen. / Nielsen, Vance G; Kulin, Wendi; Lawall, John Samuel; Macfarland, Felesia Nancy; Chen, Andrew; Hadley, Heidi Adelleen; Dadeppo, Adam James; Steinbrenner, Evangelina Barbara; Matika, Ryan William.

In: CNS and Neurological Disorders - Drug Targets, Vol. 14, No. 8, 01.10.2015, p. 1079-1085.

Research output: Contribution to journalArticle

Nielsen, VG, Kulin, W, Lawall, JS, Macfarland, FN, Chen, A, Hadley, HA, Dadeppo, AJ, Steinbrenner, EB & Matika, RW 2015, 'Chronic migraineurs form carboxyhemefibrinogen and iron-bound fibrinogen', CNS and Neurological Disorders - Drug Targets, vol. 14, no. 8, pp. 1079-1085.
Nielsen VG, Kulin W, Lawall JS, Macfarland FN, Chen A, Hadley HA et al. Chronic migraineurs form carboxyhemefibrinogen and iron-bound fibrinogen. CNS and Neurological Disorders - Drug Targets. 2015 Oct 1;14(8):1079-1085.
Nielsen, Vance G ; Kulin, Wendi ; Lawall, John Samuel ; Macfarland, Felesia Nancy ; Chen, Andrew ; Hadley, Heidi Adelleen ; Dadeppo, Adam James ; Steinbrenner, Evangelina Barbara ; Matika, Ryan William. / Chronic migraineurs form carboxyhemefibrinogen and iron-bound fibrinogen. In: CNS and Neurological Disorders - Drug Targets. 2015 ; Vol. 14, No. 8. pp. 1079-1085.
@article{01f5f7d1b40a433c99a6edebe3e64f75,
title = "Chronic migraineurs form carboxyhemefibrinogen and iron-bound fibrinogen",
abstract = "Chronic migraine (CM) is a disabling painful condition that is associated with dementia and thrombotic disease. It has been proposed that carbon monoxide (CO) and iron may play a role in CM, and CO and iron are products of the heme oxygenase system which is widespread within the brain. Further, CO and iron enhance plasmatic coagulation in part via a fibrinogen-dependent mechanism. Thus, our goal was to determine whether patients with CM had experienced carboxyhemefibrinogen formation, iron bound fibrinogen formation and plasmatic hypercoagulability. Nonsmokers with CM were recruited after informed, written consent. Blood was collected, anticoagulated with sodium citrate, and then centrifuged with plasma stored at -80ºC. Carboxyhemefibrinogen formation, iron bound fibrinogen formation and coagulation kinetics were determined via thrombelastographic methods. Patient results were compared with laboratory values generated from normal control plasmas. Incidence (95{\%} confidence intervals) of the various parameters was determined using the Clopper-Pearson method. Twenty-six CM patients (24 female) were recruited; they were 46±12 years old. With regard to fibrinogen modification, 88.5{\%} (69.8{\%}-97.6{\%}) of CM patients had formation of carboxyhemefibrinogen, iron bound fibrinogen, or both. With regard to coagulation, 42.3{\%} (23.4{\%}-63.1{\%}) of patients had abnormally decreased time to clot initiation, 80.8{\%} (60.6{\%}-93.4{\%}) had abnormally large velocity of clot formation, and 46.2{\%} (26.6{\%}-66.7{\%}) had abnormally strong clot strength. Patients with CM have a large incidence of carboxyhemefibrinogen and iron bound fibrinogen formation and hypercoagulability. Confirmatory and potential therapeutic clinical trials targeting CO and iron modified hypercoagulation as a source of pain and vascular disease in CM patients are indicated.",
keywords = "Carbon monoxide, Fibrinogen, Iron, Migraine, Thrombelastography, Vascular disease",
author = "Nielsen, {Vance G} and Wendi Kulin and Lawall, {John Samuel} and Macfarland, {Felesia Nancy} and Andrew Chen and Hadley, {Heidi Adelleen} and Dadeppo, {Adam James} and Steinbrenner, {Evangelina Barbara} and Matika, {Ryan William}",
year = "2015",
month = "10",
day = "1",
language = "English (US)",
volume = "14",
pages = "1079--1085",
journal = "CNS and Neurological Disorders - Drug Targets",
issn = "1871-5273",
publisher = "Bentham Science Publishers B.V.",
number = "8",

}

TY - JOUR

T1 - Chronic migraineurs form carboxyhemefibrinogen and iron-bound fibrinogen

AU - Nielsen, Vance G

AU - Kulin, Wendi

AU - Lawall, John Samuel

AU - Macfarland, Felesia Nancy

AU - Chen, Andrew

AU - Hadley, Heidi Adelleen

AU - Dadeppo, Adam James

AU - Steinbrenner, Evangelina Barbara

AU - Matika, Ryan William

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Chronic migraine (CM) is a disabling painful condition that is associated with dementia and thrombotic disease. It has been proposed that carbon monoxide (CO) and iron may play a role in CM, and CO and iron are products of the heme oxygenase system which is widespread within the brain. Further, CO and iron enhance plasmatic coagulation in part via a fibrinogen-dependent mechanism. Thus, our goal was to determine whether patients with CM had experienced carboxyhemefibrinogen formation, iron bound fibrinogen formation and plasmatic hypercoagulability. Nonsmokers with CM were recruited after informed, written consent. Blood was collected, anticoagulated with sodium citrate, and then centrifuged with plasma stored at -80ºC. Carboxyhemefibrinogen formation, iron bound fibrinogen formation and coagulation kinetics were determined via thrombelastographic methods. Patient results were compared with laboratory values generated from normal control plasmas. Incidence (95% confidence intervals) of the various parameters was determined using the Clopper-Pearson method. Twenty-six CM patients (24 female) were recruited; they were 46±12 years old. With regard to fibrinogen modification, 88.5% (69.8%-97.6%) of CM patients had formation of carboxyhemefibrinogen, iron bound fibrinogen, or both. With regard to coagulation, 42.3% (23.4%-63.1%) of patients had abnormally decreased time to clot initiation, 80.8% (60.6%-93.4%) had abnormally large velocity of clot formation, and 46.2% (26.6%-66.7%) had abnormally strong clot strength. Patients with CM have a large incidence of carboxyhemefibrinogen and iron bound fibrinogen formation and hypercoagulability. Confirmatory and potential therapeutic clinical trials targeting CO and iron modified hypercoagulation as a source of pain and vascular disease in CM patients are indicated.

AB - Chronic migraine (CM) is a disabling painful condition that is associated with dementia and thrombotic disease. It has been proposed that carbon monoxide (CO) and iron may play a role in CM, and CO and iron are products of the heme oxygenase system which is widespread within the brain. Further, CO and iron enhance plasmatic coagulation in part via a fibrinogen-dependent mechanism. Thus, our goal was to determine whether patients with CM had experienced carboxyhemefibrinogen formation, iron bound fibrinogen formation and plasmatic hypercoagulability. Nonsmokers with CM were recruited after informed, written consent. Blood was collected, anticoagulated with sodium citrate, and then centrifuged with plasma stored at -80ºC. Carboxyhemefibrinogen formation, iron bound fibrinogen formation and coagulation kinetics were determined via thrombelastographic methods. Patient results were compared with laboratory values generated from normal control plasmas. Incidence (95% confidence intervals) of the various parameters was determined using the Clopper-Pearson method. Twenty-six CM patients (24 female) were recruited; they were 46±12 years old. With regard to fibrinogen modification, 88.5% (69.8%-97.6%) of CM patients had formation of carboxyhemefibrinogen, iron bound fibrinogen, or both. With regard to coagulation, 42.3% (23.4%-63.1%) of patients had abnormally decreased time to clot initiation, 80.8% (60.6%-93.4%) had abnormally large velocity of clot formation, and 46.2% (26.6%-66.7%) had abnormally strong clot strength. Patients with CM have a large incidence of carboxyhemefibrinogen and iron bound fibrinogen formation and hypercoagulability. Confirmatory and potential therapeutic clinical trials targeting CO and iron modified hypercoagulation as a source of pain and vascular disease in CM patients are indicated.

KW - Carbon monoxide

KW - Fibrinogen

KW - Iron

KW - Migraine

KW - Thrombelastography

KW - Vascular disease

UR - http://www.scopus.com/inward/record.url?scp=84945400017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945400017&partnerID=8YFLogxK

M3 - Article

C2 - 26295816

AN - SCOPUS:84945400017

VL - 14

SP - 1079

EP - 1085

JO - CNS and Neurological Disorders - Drug Targets

JF - CNS and Neurological Disorders - Drug Targets

SN - 1871-5273

IS - 8

ER -